British Columbia Centre on Substance Use, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Vancouver Coastal Health, Vancouver, BC, Canada.
Int J Drug Policy. 2024 Sep;131:104547. doi: 10.1016/j.drugpo.2024.104547. Epub 2024 Aug 17.
The ongoing overdose crisis in Canada has prompted efforts to increase access to a "safer supply" of prescribed alternatives to the unregulated drug supply. While safer supply programs predominantly distribute hydromorphone tablets, the Safer Alternatives for Emergency Response (SAFER) program in Vancouver, Canada offers a range of prescribed alternatives, including fentanyl patches. However, little is known about the effectiveness of fentanyl patches as safer supply. Drawing on the perspectives and experiences of program participants, we sought to qualitatively evaluate the effectiveness of the SAFER fentanyl patch program in meeting its intended aims, including reducing risk of overdose by decreasing reliance on the unregulated drug supply.
As part of a larger mixed-methods evaluation of SAFER, semi-structured qualitative interviews were conducted with 17 fentanyl patch program participants between February 2022 and April 2023. Thematic analysis of interview data focused on program engagement, experiences, impacts, and challenges.
The flexible program structure, including lack of need for daily dispensation, the extended missed dose protocol, and community pharmacy patch distribution fostered engagement and enhanced autonomy. Improved management of withdrawal symptoms and cravings due to steady transdermal dosing led to reduced unregulated drug use and overdose risk. Participants also experienced economic benefits and improvements in overall health and quality of life. However, skin irritation and patch adhesion issues were key barriers to program retention.
Our findings demonstrate the value of including fentanyl patch safer supply in the substance use continuum of care and offer insights for innovations in delivery of this intervention.
加拿大目前的阿片类药物过量危机促使人们努力增加获得受监管替代药物的机会,以替代不受监管的药物供应。虽然安全供应计划主要分发氢吗啡酮片剂,但加拿大温哥华的安全替代药物应急响应计划(SAFER)提供了一系列受监管的替代药物,包括芬太尼贴片。然而,对于芬太尼贴片作为安全供应的有效性知之甚少。本研究从项目参与者的观点和经验出发,旨在定性评估 SAFER 芬太尼贴片计划实现其预期目标的效果,包括通过减少对不受监管药物供应的依赖来降低过量风险。
作为 SAFER 更广泛的混合方法评估的一部分,我们于 2022 年 2 月至 2023 年 4 月期间对 17 名芬太尼贴片计划参与者进行了半结构式定性访谈。对访谈数据的主题分析集中在计划参与、经验、影响和挑战上。
灵活的计划结构,包括无需每日配药、延长漏服剂量方案和社区药房贴片分发,促进了参与度并增强了自主权。由于稳定的透皮给药,戒断症状和渴望得到了更好的管理,导致不受监管的药物使用和过量风险降低。参与者还体验到了经济上的好处,并改善了整体健康和生活质量。然而,皮肤刺激和贴片粘附问题是计划保留的主要障碍。
我们的研究结果表明,在物质使用护理连续体中纳入芬太尼贴片安全供应具有价值,并为该干预措施的提供提供了创新的见解。